{"id":"https://openalex.org/W4390967494","doi":"https://doi.org/10.1200/po.22.00667","title":"Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial","display_name":"Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial","publication_year":2024,"publication_date":"2024-01-18","ids":{"openalex":"https://openalex.org/W4390967494","doi":"https://doi.org/10.1200/po.22.00667","pmid":"https://pubmed.ncbi.nlm.nih.gov/38237097"},"language":"en","primary_location":{"id":"doi:10.1200/po.22.00667","doi":"https://doi.org/10.1200/po.22.00667","is_oa":false,"landing_page_url":"https://doi.org/10.1200/po.22.00667","pdf_url":null,"source":{"id":"https://openalex.org/S4210227748","display_name":"JCO Precision Oncology","issn_l":"2473-4284","issn":["2473-4284"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Precision Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032785430","display_name":"Ian E. Krop","orcid":"https://orcid.org/0000-0002-6380-5944","observed_orcids":["https://orcid.org/0000-0002-6380-5944"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian E. Krop","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":"https://orcid.org/0000-0002-6380-5944","affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069636342","display_name":"Lorenza Mittempergher","orcid":"https://orcid.org/0000-0003-3425-3965","observed_orcids":["https://orcid.org/0000-0003-3425-3965"]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Lorenza Mittempergher","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":"https://orcid.org/0000-0003-3425-3965","affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079235139","display_name":"Joseph Nathaniel Paulson","orcid":"https://orcid.org/0000-0001-8221-7139","observed_orcids":["https://orcid.org/0000-0001-8221-7139"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph N. Paulson","raw_affiliation_strings":["Genentech, San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0001-8221-7139","affiliations":[{"raw_affiliation_string":"Genentech, San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001814176","display_name":"Fabrice Andr\u00e9","orcid":"https://orcid.org/0000-0001-5795-8357","observed_orcids":["https://orcid.org/0000-0001-5795-8357","https://orcid.org/0000-0002-6272-6048"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fabrice Andre","raw_affiliation_strings":["Gustave Roussy, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056811246","display_name":"Herve R. Bonnefoi","orcid":"https://orcid.org/0000-0003-4293-9748","observed_orcids":["https://orcid.org/0000-0003-4293-9748"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Herve Bonnefoi","raw_affiliation_strings":["Bergonie Cancer Institute, Bordeaux, France"],"raw_orcid":"https://orcid.org/0000-0003-4293-9748","affiliations":[{"raw_affiliation_string":"Bergonie Cancer Institute, Bordeaux, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010278367","display_name":"Sherene Loi","orcid":"https://orcid.org/0000-0001-6137-9171","observed_orcids":["https://orcid.org/0000-0001-6137-9171"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Sherene Loi","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, Australia"],"raw_orcid":"https://orcid.org/0000-0001-6137-9171","affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, Australia","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087559224","display_name":"Sibylle Loibl","orcid":"https://orcid.org/0000-0001-6488-4958","observed_orcids":["https://orcid.org/0000-0001-6488-4958"]},"institutions":[{"id":"https://openalex.org/I114090438","display_name":"Goethe University Frankfurt","ror":"https://ror.org/04cvxnb49","country_code":"DE","type":"education","lineage":["https://openalex.org/I114090438"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Sibylle Loibl","raw_affiliation_strings":["Goethe University, Frankfurt, Germany"],"raw_orcid":"https://orcid.org/0000-0001-6488-4958","affiliations":[{"raw_affiliation_string":"Goethe University, Frankfurt, Germany","institution_ids":["https://openalex.org/I114090438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040290360","display_name":"Richard D. Gelber","orcid":"https://orcid.org/0000-0001-8270-8712","observed_orcids":["https://orcid.org/0000-0001-8270-8712"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210138586","display_name":"Frontier Science & Technology Research Foundation, Inc.","ror":"https://ror.org/04hbhf775","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210138586"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard D. Gelber","raw_affiliation_strings":["Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science Foundation, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-8270-8712","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science Foundation, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210138586"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000083098","display_name":"Carmela Aves Caballero","orcid":"https://orcid.org/0000-0002-3586-6598","observed_orcids":["https://orcid.org/0000-0002-3586-6598"]},"institutions":[{"id":"https://openalex.org/I35141943","display_name":"Breast International Group","ror":"https://ror.org/0092p0v85","country_code":"BE","type":"nonprofit","lineage":["https://openalex.org/I35141943"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Carmela Caballero","raw_affiliation_strings":["Breast International Group (BIG), Brussels, Belgium"],"raw_orcid":"https://orcid.org/0000-0002-3586-6598","affiliations":[{"raw_affiliation_string":"Breast International Group (BIG), Brussels, Belgium","institution_ids":["https://openalex.org/I35141943"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110640720","display_name":"Rajith Bhaskaran","orcid":"https://orcid.org/0000-0001-8710-2373","observed_orcids":["https://orcid.org/0000-0001-8710-2373"]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Rajith Bhaskaran","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009879229","display_name":"Christa Dreezen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Christa Dreezen","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042373823","display_name":"Andrea R. Menicucci","orcid":"https://orcid.org/0000-0003-4242-6213","observed_orcids":["https://orcid.org/0000-0003-4242-6213"]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Andrea R. Menicucci","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":"https://orcid.org/0000-0003-4242-6213","affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028266055","display_name":"Ren\u00e9 Bernards","orcid":"https://orcid.org/0000-0001-8677-3423","observed_orcids":["https://orcid.org/0000-0001-8677-3423"]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Rene Bernards","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":"https://orcid.org/0000-0001-8677-3423","affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014135109","display_name":"Laura van \u2018t Veer","orcid":"https://orcid.org/0000-0002-9838-8298","observed_orcids":["https://orcid.org/0000-0002-9838-8298"]},"institutions":[{"id":"https://openalex.org/I4210146442","display_name":"Agendia (Netherlands)","ror":"https://ror.org/03txpx007","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210146442"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Laura J. van \u2019t Veer","raw_affiliation_strings":["Agendia, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agendia, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I4210146442"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087380706","display_name":"Martine J Piccart","orcid":"https://orcid.org/0000-0001-9068-8504","observed_orcids":["https://orcid.org/0000-0001-9068-8504"]},"institutions":[{"id":"https://openalex.org/I35141943","display_name":"Breast International Group","ror":"https://ror.org/0092p0v85","country_code":"BE","type":"nonprofit","lineage":["https://openalex.org/I35141943"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Martine J. Piccart","raw_affiliation_strings":["Breast International Group (BIG), Brussels, Belgium"],"raw_orcid":"https://orcid.org/0000-0001-9068-8504","affiliations":[{"raw_affiliation_string":"Breast International Group (BIG), Brussels, Belgium","institution_ids":["https://openalex.org/I35141943"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5087380706"],"corresponding_institution_ids":["https://openalex.org/I35141943"],"apc_list":null,"apc_paid":null,"fwci":0.2719,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.4438705,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"8","issue":"8","first_page":"e2200667","last_page":"e2200667"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.05609999969601631,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/molecular-subtyping","display_name":"molecular subtyping","score":0.7689999938011169},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8989999890327454},{"id":"https://openalex.org/keywords/invasive-disease-free-survival","display_name":"invasive disease-free survival","score":0.8769999742507935},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7990000247955322},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.4880000054836273},{"id":"https://openalex.org/keywords/prognostic-subtypes","display_name":"prognostic subtypes","score":0.4880000054836273}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.7402453422546387},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6666065454483032},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6167762279510498},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6145483255386353},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5984290838241577},{"id":"https://openalex.org/C83852419","wikidata":"https://www.wikidata.org/wiki/Q2713292","display_name":"Subtyping","level":2,"score":0.588479220867157},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.555933952331543},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5213450193405151},{"id":"https://openalex.org/C2778024521","wikidata":"https://www.wikidata.org/wiki/Q55639806","display_name":"Basal (medicine)","level":3,"score":0.4687258005142212},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.439956933259964},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.410376638174057},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3816480040550232},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.339712530374527},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.14816486835479736},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/po.22.00667","doi":"https://doi.org/10.1200/po.22.00667","is_oa":false,"landing_page_url":"https://doi.org/10.1200/po.22.00667","pdf_url":null,"source":{"id":"https://openalex.org/S4210227748","display_name":"JCO Precision Oncology","issn_l":"2473-4284","issn":["2473-4284"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Precision Oncology","raw_type":"journal-article"},{"id":"pmid:38237097","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38237097","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO precision oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.979200005531311}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1917773519","https://openalex.org/W1964969316","https://openalex.org/W1996778928","https://openalex.org/W1999676514","https://openalex.org/W2032968026","https://openalex.org/W2033199493","https://openalex.org/W2095156669","https://openalex.org/W2095861620","https://openalex.org/W2101979288","https://openalex.org/W2125511612","https://openalex.org/W2149900235","https://openalex.org/W2196212938","https://openalex.org/W2241896073","https://openalex.org/W2379981061","https://openalex.org/W2524983680","https://openalex.org/W2588881638","https://openalex.org/W2607518013","https://openalex.org/W2624590002","https://openalex.org/W2755331429","https://openalex.org/W2756562465","https://openalex.org/W2889266533","https://openalex.org/W2895830070","https://openalex.org/W2897588803","https://openalex.org/W2939027752","https://openalex.org/W2947111998","https://openalex.org/W2948369249","https://openalex.org/W2996055214","https://openalex.org/W3011002637","https://openalex.org/W3032393937","https://openalex.org/W4220686028","https://openalex.org/W4281559326","https://openalex.org/W4285602033","https://openalex.org/W4292297408","https://openalex.org/W4317485907"],"related_works":["https://openalex.org/W3132815494","https://openalex.org/W4295921314","https://openalex.org/W7149604560","https://openalex.org/W4224941668","https://openalex.org/W4220713429","https://openalex.org/W4396597683","https://openalex.org/W2402196471","https://openalex.org/W4381250908","https://openalex.org/W3133041857","https://openalex.org/W4220686028"],"abstract_inverted_index":{"PURPOSE:":[0],"At":[1],"the":[2,5,43,53,58,82,246],"primary":[3,114],"analysis,":[4],"APHINITY":[6,54],"trial":[7],"reported":[8],"a":[9,67,103,178,239],"statistically":[10],"significant":[11,196],"but":[12],"modest":[13],"benefit":[14,60,308],"of":[15,72,80,153,183,187,248,268],"adding":[16],"pertuzumab":[17,249],"to":[18,77,218,229,256],"standard":[19],"adjuvant":[20],"chemotherapy":[21],"plus":[22],"trastuzumab":[23],"in":[24,198],"patients":[25,51,74,132,142,299],"with":[26,109,138,232,259,273,285,300],"histologically":[27,269],"confirmed":[28,270],"human":[29],"epidermal":[30],"growth":[31],"factor":[32],"receptor":[33],"2":[34],"(HER2)-positive":[35],"early-stage":[36],"breast":[37,85],"cancer.":[38],"This":[39],"study":[40,70],"evaluated":[41,126],"whether":[42],"80-gene":[44],"molecular":[45],"subtyping":[46],"signature":[47],"(80-GS)":[48],"could":[49],"identify":[50],"within":[52],"population":[55],"who":[56],"derive":[57],"most":[59],"from":[61,309],"dual":[62,191],"anti-HER2":[63],"therapy.":[64],"METHODS:":[65],"In":[66],"nested":[68],"case-control":[69],"design":[71],"1,023":[73],"(matched":[75],"event":[76,222],"control":[78],"ratio":[79],"3:1),":[81],"80-GS":[83,97,147,203,265],"classified":[84,148],"tumors":[86,108,154,175,189,213,237,272,279,305],"into":[87],"functional":[88,105],"luminal":[89,156],"type,":[90,92,157,164],"HER2":[91,163,235,303],"or":[93],"basal":[94,171,211],"type.":[95,172],"Additionally,":[96],"distinguished":[98],"tumor":[99],"subtypes":[100,204,208],"that":[101],"exhibited":[102],"single-dominant":[104],"pathway":[106],"versus":[107],"multiple":[110],"activated":[111],"pathways.":[112],"The":[113,146,264],"end":[115],"point":[116],"was":[117,194],"invasive":[118],"disease-free":[119],"survival":[120],"(IDFS).":[121],"Hazard":[122],"ratios":[123],"(HRs)":[124],"were":[125,143,190,214],"by":[127],"Cox":[128],"regression.":[129],"After":[130],"excluding":[131],"without":[133],"appropriate":[134],"consent":[135],"and":[136,165,185,206,288],"those":[137],"missing":[139],"data,":[140],"964":[141],"included.":[144],"RESULTS:":[145],"50%":[149],"(n":[150,159,167],"=":[151,160,168],"479)":[152],"as":[155,162,170],"28%":[158],"275)":[161],"22%":[166],"209)":[169],"Most":[173],"luminal-type":[174],"(86%)":[176],"displayed":[177,238],"single-activated":[179],"pathway,":[180],"whereas":[181],"49%":[182],"HER2-type":[184],"42%":[186],"basal-type":[188],"activated.":[192],"There":[193],"no":[195],"difference":[197],"IDFS":[199,221],"among":[200],"different":[201],"conventional":[202],"(single-":[205],"dual-activated":[207],"combined).":[209],"However,":[210],"single-subtype":[212,236,278,304],"significantly":[215],"more":[216],"likely":[217],"have":[219],"an":[220,281],"(hazard":[223,250],"ratio,":[224,251],"1.69":[225],"[95%":[226,253],"CI,":[227,254],"1.12":[228],"2.54])":[230],"compared":[231,258,284],"other":[233,261,286],"subtypes.":[234,262],"trend":[240],"toward":[241],"greater":[242],"beneficial":[243],"effect":[244],"on":[245],"addition":[247],"0.56":[252],"0.27":[255],"1.16])":[257],"all":[260],"CONCLUSION:":[263],"identified":[266],"subgroups":[267,287],"HER2-positive":[271],"distinct":[274],"biological":[275],"characteristics.":[276],"Basal":[277],"exhibit":[280],"inferior":[282],"prognosis":[283],"may":[289,306],"be":[290],"candidates":[291],"for":[292],"additional":[293],"therapeutic":[294],"strategies.":[295],"Preliminary":[296],"results":[297],"suggest":[298],"HER2-positive,":[301],"genomically":[302],"particularly":[307],"added":[310],"pertuzumab,":[311],"which":[312],"warrants":[313],"further":[314],"investigation.":[315]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-01-19T00:00:00"}